Description     Claims     Drawing  

US20130156796A   [0003] 
US20120156217A   [0004]  [0010]  [0032]  [0078] 
US7628986B   [0009] 
US7589180B   [0009]  [0009] 
WO2009025846A   [0010] 
WO2012100346A   [0010]  [0034]  [0068] 
US20050169933A   [0027] 
US6235883B   [0037]  [0090] 
US7807798B   [0037]  [0090] 
US5208020A   [0045] 
US8088387B   [0045] 
US6441163B   [0045] 
US3773919A   [0054] 

Cancer Res.   [0005] 
Clin Cancer Res   [0006]  [0088] 
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8   [0025] 
Eur. J. Biochem.   [0027]  [0028]  [0046] 
J. Applied Biochem.   [0027]  [0028]  [0046] 
Bioconjugate Chem.   [0027]  [0028]  [0046] 
Proceedings of the 104th Annual Meeting of the American Association for Cancer Research   [0032] 
Cancer Res   [0032] 
Remington's Pharmaceutical Sciences   [0052] 
Chemotherapy Service   [0063] 
MABs   [0083] 
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability   [0087] 
FDA Package Insert for Kadcyla™   [0087] 
Nature Biotechnology   [0102]